Dermatology product maker Medicis Pharmaceutical Corp. on Thursday said the Food and Drug Administration has approved a wider use for the company's Vanos skin medication.
The wider use allows Medicis to market the steroid as a primary treatment for skin inflammation and itching for patients 12 and older. Such condition include eczema and exposure to poison ivy.
The drug was approved last year, and launched in April, as a treatment for plaque-type psoriasis, a chronic condition of red, scaly inflamed skin
